Effects of treatment with 177Lu-DOTA-Tyr3-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 644-653

  Bernhardt, Peter ^a   Oddstig, Jenny ^a   Kölby, Lars ^a   Nilsson, Ola ^a   Ahlman, Håkan ^a   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

177Lu DOTA0 Tyr3 octreotate; Fractionation; Midgut carcinoid; Radionuclide therapy; Somatostatin receptors

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DOTATATE IN 111; DOTATATE LU 177; INDIUM 111; LUTETIUM 177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOID; CELL ACTIVITY; CELL DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; INTESTINE CANCER; MOUSE; NONHUMAN; NUDE MOUSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; CARCINOID TUMOR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; LUTETIUM; MICE; MICE, NUDE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35848949321     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.333     Document Type: Article

References (26)

1. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998;25(7):668.
2. 3] octreotate for somatostatin receptor - targeted radionuclide therapy. Int J Cancer 2001;92(5):628.
3. Kölby L, Bernhardt P, Johanson V, et al. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 2005;93(10):1144.
4. 3-octreotate in an animal model. J Nucl Med 2004;45(9):1542.
5. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl. 1):83S.
6. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with three radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl. 1):62S.
7. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43(5):610.
8. 3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66(6):393.
9. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30(3):417.
10. 0]octreotide in patients. Eur J Nucl Med 2001; 28(9):1319.
11. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor - targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32(2):133.
12. Kölby L, Bernhardt P, Ahlman H, et al. A transplantable human carcinoid as model for somatostatin receptormediated and amine transporter-mediated radionuclide uptake. Am J Pathol 2001;158(2):745.
13. Bernhardt P, Benjegård SA, Kölby L, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor - expressing tumors. Int J Radiat Oncol Biol Phys 2001;51(2):514.
14. Ruan S, O'Donoghue JA, Larson SM, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med 2000;41(11):1905.
15. Capello A, Krenning E, Bernard B, et al. (111)In-labelled somatostatin analogs in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005;32(11):1288.
16. Behe M, Koller S, Püsken M, et al. Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 2004;31:S237.
17. Oddstig J, Bernhardt P, Nilsson O, et al. Radiation-induced up-regulation of somatostatin receptor expression in small-cell lung cancer in vitro. Nucl Med Biol 2006;33(7):841.
18. 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor. Nucl Med Biol 2001;28(1):67.
19. Cremonesi M, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: Implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26(8):877.
20. Forster GJ, Engelbach MJ, Brockmann JJ, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor - positive tumours: Comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 2001;28(12):1743.
21. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60(9):2497.
22. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial versus subcutaneous tumors. Proc Natl Acad Sci USA 2001;98(8):4628.
23. Znati CA, Rosenstein M, McKee TD, et al. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res 2003;9(15):5508.
24. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94(Suppl. 4):1332.
25. Rolleman EJ, Krenning EP, Bernard BF, et al. Longterm toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging 2007;34(2):219.
26. Forrer F, Valkema R, Kwekkeboom DJ, et al. Neuroendocrine tumors: Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21(1):111.